|
Brazil Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Brazil Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Brazil.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Brazilian pharmaceutical and healthcare industry.
Competitive intelligence, Brazilian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Brazilian market.
The Brazil Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Brazil Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Brazilian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Brazil to test other views – a key input for successful budgeting and strategic business planning in the Brazilian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Brazilian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Brazil.
- Exploit The Latest Competitive Brazilian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Brazil.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Brazil Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Brazil Pharmaceuticals And Healthcare Industry SWOT |
| Brazil Political SWOT |
| Brazil Economic SWOT |
| Brazil Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Americas Pharmaceutical Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Brazil – Market Summary |
| Regulatory Regime |
| Intellectual Property |
| Regulator Interference |
| Data Protection |
| Compulsory Licensing |
| Intellectual Property Environment |
| Pricing And Reimbursement Issues |
| Tax Burden On Pharmaceuticals |
| Over-The-Counter Regulations |
| Advertising |
| Other Regulatory Issues |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Domestic Pharmaceutical Industry |
| PROFARMA Initiative |
| Research and Development |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Brazilian Drug Market Trends |
| Key Growth Factors – Industry |
| Table: Brazilian Health Expenditure Trends |
Chapter - Key Growth Factors – Macroeconomic |
| Table: Brazil - Economic Activity |
| Prescription Market Forecast |
| Table: Brazil's Prescription Drug Market Trends (US$mn unless otherwise stated) |
| Generics Market Forecast |
| Table: Brazil's Generics And Patented Market Forecasts |
| OTC Market Forecast |
| Table: Brazil's OTC Market Trends (US$mn unless otherwise stated) |
| Medical Device Market Forecast |
| Table: Brazil Medical Device Forecasts (US$mn unless otherwise stated) |
| Table: Pharmaceutical Trade Data And Forecasts (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Socio-Demographic Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Leading Products |
| Innovative Drugmakers |
| Generic Drugmakers |
| OTC Sector |
| Distribution Sector |
| Retail Market |
Chapter - Company Monitor |
| Leading Multinational Companies |
| Sanofi-Aventis |
| Pfizer |
| Merck & Co |
| Novartis |
| GlaxoSmithKline (GSK) |
| Roche |
| Nycomed (Altana Pharma) |
| Merck KGaA |
| Novo Nordisk |
| Indigenous Manufacturing Sector |
| Aché / Biosintética |
| EMS Sigma |
| Eurofarma |
| Medley |
Chapter - Country Snapshot: Brazil Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2000-2003 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 1999-2004 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 1996-2002 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Brazil Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Brazil is one of the most attractive countries in Latin America for multinational pharmaceutical companies. Pharmaceutical market growth stepped up a gear in 2008, registering an increase of 9.5% year-on-year (y-o-y). Sales, including hospitals and other public and private institutions, reached BRL30.8bn (US$16.7bn), showing resilience to the economic downturn and reinforcing Brazil's position as a rapidly expanding and attractive market – one that remains the tenth largest globally. Over the next five years, BMI forecasts that sales of pharmaceuticals will increase from US$16.7bn to US$28.2bn, representing a compound annual growth rate (CAGR) of 11.0%.
In BMI’s Pharmaceuticals & Healthcare Business Environment Rankings for Q209, Brazil places fourth in the Americas region. Despite large market size and high growth rates and low generic penetration, a small pensionable population and weak intellectual property scores will limit progression up the table over the medium term.
Brazil’s use of compulsory licensing to not only to save cost, but also boost production, remains a major risk to multinationals. In early 2009 state-owned pharmaceutical company Farmanguinhos began producing efavirenz, following the National Health Surveillance Agency (ANVISA)’s approval. The Ministry of Health received its first order of 2.1mn tablets on February 16 2009, with a total order for 15mn over the course of the year. By 2010, the target for production is 30mn, which will cover total demand of the population, essentially eliminating the need for imports of the drug. Efavirenz is used by 85,000 of the 185,000 people in Brazil's AIDS programme. BMI questions whether producing a generic version of a patented drug, which could be procured cheaper elsewhere, essentially undermines the fundamentals of the original compulsory licence – to save money.
Despite their relatively low penetration, generics continue to capture market share in Brazil. Sales of generic drugs rose 33% in 2008, while, in volume terms, the number of units sold rose 18.9% to 277.1mn. Despite an evident reluctance to use, we believe that prevailing economic conditions should help further develop the market over the course of 2009.
Despite certain market constraints, innovative companies are still performing strongly. AstraZeneca's sales in Brazil grew at double that of the retail pharmaceutical market in 2008, placing the drugmaker in ninth position, with a market share of 3.3%. Meanwhile, Switzerland-based Roche also showed strong performance in Brazil in 2008, with sales growing 9% to BRL1.7bn (US$0.95bn).
|
Brazil Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |